Humanin: The Neuroprotective Peptide Encoded in Your Mitochondrial DNA

For most of the 20th century, mitochondria were taught as one thing: the cellular power plant. The organelle that runs the Krebs cycle, churns out ATP, and keeps the lights on. Then in 2001, a small Japanese research team looking at brain tissue from a patient who had escaped Alzheimer's disease found something that didn't fit that model — a 21-amino-acid peptide encoded directly in the mitochondrial genome, doing something that had nothing to do with energy production. It was protecting neurons.

That peptide is Humanin. And its discovery cracked open a question that's been driving longevity research ever since: if mitochondria are encoding their own signaling peptides, then mitochondria aren't just an energy organelle — they're a signaling organ.

Most biohackers in this audience already know MOTS-c, the metabolic mitochondrial-derived peptide that activates AMPK and mimics the effects of fasting. Humanin is its older, more neurologically focused sibling. Same genome. Different job. And the research on its role in cognitive aging, cardiovascular health, and lifespan is — frankly — some of the most interesting longevity science of the last twenty years.

Here's what it is, how it works, and why a class of peptides almost no one outside academic longevity labs is talking about may turn out to be one of the most important targets in aging biology.

What Is Humanin?

Humanin is a mitochondrial-derived peptide (MDP) — a short signaling peptide encoded inside mitochondrial DNA rather than nuclear DNA. Specifically, the open reading frame for Humanin sits inside the 12S rRNA region of the mitochondrial genome. This is unusual: most signaling molecules in human biology are encoded in the nucleus, transcribed there, and then exported. Humanin is built inside the mitochondrion itself, then released into the cell and into systemic circulation.

The mature peptide is 21 amino acids long: MAPRGFSCLLLLTSEIDLPVKRRA. That sequence is small, stable, and small enough to cross the blood-brain barrier — which turns out to matter a great deal for what it does.

Humanin was first reported in 2001 by Hashimoto et al., working in the lab of Yuichi Hashimoto in Tokyo. The discovery story is worth understanding because it explains why this peptide matters. The team was screening a cDNA library generated from the surviving brain tissue of a patient with Alzheimer's disease — specifically, from the occipital lobe, a region that is largely spared from Alzheimer's pathology even in advanced cases. They were looking for any factor that might explain why those neurons survived when the rest of the brain was being destroyed.

What they pulled out was a small peptide that, when applied to neurons in culture, protected them from Alzheimer's-related toxicity. They called it Humanin — partly a nod to the human source, partly a reflection of what it appeared to do: keep neurons alive.

Since then, the field has expanded. Humanin is now known to be just one member of a family of mitochondrial-derived peptides that includes MOTS-c and the SHLPs (Small Humanin-Like Peptides 1–6). We'll come back to that family at the end.

How Humanin Works

For a peptide this small, Humanin has a surprisingly rich mechanism profile. It binds to multiple receptors, activates several intracellular pathways, and crosstalks with one of the most studied signaling axes in aging biology — IGF-1.

Receptor Binding

Humanin is known to interact with at least two receptor systems:

• FPRL1 (formyl peptide receptor-like 1) — a G-protein-coupled receptor expressed on neurons and immune cells. Humanin binding here triggers anti-apoptotic signaling and modulates inflammation.
• CNTFR / WSX-1 / gp130 trimeric complex — the ciliary neurotrophic factor receptor complex. Through this receptor, Humanin activates STAT3 signaling, a pathway tightly linked to neuronal survival.

Downstream Pathways

Once Humanin binds, the intracellular cascade looks like this:

• STAT3 activation — drives expression of survival and anti-inflammatory genes. STAT3 is the workhorse pathway behind a lot of Humanin's neuroprotective effect.
• PI3K / Akt activation — the canonical cell survival pathway. Akt phosphorylation suppresses pro-apoptotic signals and supports glucose handling.
• Suppression of Bax translocation and caspase-3 activation — Humanin directly inhibits the mitochondrial apoptotic cascade. Bax normally migrates to the mitochondrial membrane during cell stress, opening the pore that releases cytochrome c and triggers caspase-3-mediated cell death. Humanin blocks that migration. The cell stays alive.

IGF-1 Crosstalk

Humanin also binds to IGFBP-3 (IGF-binding protein 3), modulating the bioavailability of IGF-1. This matters because IGF-1 signaling sits at the center of nearly every major aging pathway — from FOXO transcription factors to mTOR to the GH/IGF-1 axis itself. Humanin appears to fine-tune that signaling rather than simply suppress or amplify it, which fits the general pattern of mitochondrial-derived peptides acting as adaptive metabolic regulators.

Amyloid Beta Protection

The original 2001 discovery showed that Humanin protects neurons from Aβ25-35 (a toxic fragment of amyloid-beta) and from the larger Aβ1-42 plaque-forming species. The protection appears to work through both receptor-mediated survival signaling and direct binding to amyloid fibrils, which interferes with their aggregation. This is the mechanism most directly relevant to Alzheimer's research.

Key Research Findings

The Humanin literature has expanded significantly since 2001. Below are the most important threads.

Alzheimer's and Neurodegeneration

This is where the strongest preclinical signal sits. Hashimoto et al. (2001) showed that Humanin protects cortical neurons from Aβ-induced cell death. Subsequent work showed that:

• CSF and plasma Humanin levels are inversely correlated with Alzheimer's disease progression. Patients with more advanced AD show lower circulating Humanin.
• Humanin analogues with enhanced potency (such as HNG, a Ser14Gly substitution that's ~1,000× more potent than wild-type Humanin) protect neurons in animal models of AD.
• Intracerebroventricular and intranasal delivery have both been studied for CNS targeting — intranasal in particular bypasses the blood-brain barrier limitation and is an active area of delivery research.

Metabolic Effects

Muzumdar et al. (2009) and follow-up work from the Albert Einstein College of Medicine demonstrated that Humanin improves insulin sensitivity in obese and aged mouse models, reduces hepatic glucose production, and protects against atherosclerotic plaque formation in ApoE-knockout mice fed a high-fat diet. The metabolic mechanism overlaps with — but is distinct from — MOTS-c's AMPK-driven effects. Humanin appears to act more centrally (hypothalamic insulin signaling) and through cardioprotective pathways.

Longevity and Centenarian Studies

This is the thread that converted a lot of longevity researchers to taking MDPs seriously. Work from Pinchas Cohen's group at the USC Leonard Davis School of Gerontology — including data from the CALERIE caloric restriction trial and centenarian offspring cohorts — has shown:

• Humanin levels decline roughly 40% between age 20 and age 60. The decline accelerates in metabolically unhealthy individuals.
• Higher circulating Humanin is associated with extended lifespan in mouse models and with cardiovascular protection in human cohorts.
• Centenarians and the offspring of centenarians have significantly higher Humanin levels than age-matched controls. Low Humanin is predictive of cardiovascular risk independent of conventional markers.

Cohen's group has explicitly framed Humanin as a candidate longevity biomarker — a number worth tracking in the same conversation as klotho, NAD+, and IGF-1.

Dopaminergic Neuroprotection

A smaller but interesting body of work has examined Humanin's effects on dopaminergic neurons — the cell population that's progressively lost in Parkinson's disease. In MPTP and rotenone models of parkinsonism, Humanin and its analogues protect dopaminergic neurons from oxidative and mitochondrial-toxin-induced death. The Parkinson's-relevance research is earlier-stage than the Alzheimer's literature but mechanistically consistent.

The SHLP Family

Humanin isn't alone. In 2015, Cohen's group identified six Small Humanin-Like Peptides (SHLP1–SHLP6), each encoded in different regions of the same 16S/12S rRNA mitochondrial sequence. SHLP2 in particular has emerged as a metabolic regulator with effects on insulin sensitivity, fat oxidation, and Alzheimer's pathology that overlap meaningfully with Humanin. Together with MOTS-c, the MDP family is now recognized as a coordinated mitochondrial signaling system rather than a one-off discovery.

Humanin vs. MOTS-c: A Mitochondrial Signaling Comparison

If you've read our MOTS-c article, the family resemblance will be obvious. But the two peptides do genuinely different things, which is why most thoughtful protocols stack them rather than treat them as substitutes.

The simplest framing: Humanin keeps neurons alive. MOTS-c keeps muscles metabolically young. Stacked, they cover both ends of the mitochondrial signaling axis — the anti-apoptotic / neuroprotective end and the metabolic / energy-sensing end.

Declining Humanin Levels — and Why It Matters

The single most important fact about Humanin from a longevity standpoint is this: levels decline with age. Substantially.

The Cohen lab's data shows roughly a 40% decline in circulating Humanin between age 20 and age 60. Centenarian cohorts retain higher levels than age-matched non-centenarians, and centenarian offspring inherit some of that elevation. The decline is also accelerated by:

• Chronic metabolic dysfunction (insulin resistance, type 2 diabetes, obesity)
• Chronic stress (sustained cortisol, sleep deprivation)
• Mitochondrial dysfunction generally (which makes intuitive sense — if mitochondria are damaged or scarce, they produce fewer mitochondrially-derived peptides)
• Sedentary behavior (exercise appears to acutely raise MDP levels)

The right way to read this is as a longevity biomarker, not just a peptide of academic interest. Humanin levels are a real-time readout of mitochondrial health and signaling capacity. When they fall, the system loses one of its endogenous brakes on neurodegeneration, vascular inflammation, and apoptotic stress.

This is the same pattern we see with NAD+ and the major longevity peptides: the molecules your body needs to defend itself against aging are the same molecules that decline as you age. The intervention question follows naturally.

Supplementation and Research Protocols

This article is for educational purposes only. Humanin is a research peptide not approved by the FDA for human use. Consult a healthcare professional before using any peptide.

With that on the table, here's what the research and the practitioner literature actually describe.

Forms

Humanin is typically synthesized as lyophilized (freeze-dried) powder for research use. Two forms are most commonly studied:

• Wild-type Humanin (HN) — the native 21-aa sequence.
• Humanin G (HNG) — a Ser14Gly analogue that's roughly 1,000× more potent than wild-type and the most commonly used form in animal research.

Research Doses (Animal / Preclinical)

Research protocols have used a fairly wide dose range, depending on whether the goal is metabolic, neuroprotective, or systemic effect. In the practitioner literature, typical research-context doses fall around:

• 2–4 mg per injection, subcutaneously, 3× per week.
• Cycle lengths of 4–8 weeks with off-cycles of equivalent or longer length.
• Some protocols front-load with a higher initial dose for the first 1–2 weeks, then taper.

Intranasal Delivery for CNS Targeting

For neuroprotective applications specifically, intranasal administration is being actively studied. The intranasal route bypasses the blood-brain barrier via the olfactory and trigeminal nerve pathways, delivering peptide directly to CNS tissue. For Humanin, where the brain is the target organ, intranasal is mechanistically appealing. This is one of the few peptides where intranasal isn't a workaround — it's potentially the most relevant route for the indication.

Stability and Storage

• Lyophilized: stable refrigerated (2–8°C) for extended periods; some sources support freezer storage for long-term.
• Reconstituted: refrigerate (2–8°C), use within 14–28 days depending on bacteriostatic water content. Avoid freeze-thaw cycles after reconstitution.
• Humanin is a relatively small, stable peptide — but like all peptides, it benefits from careful temperature control and minimal handling once reconstituted.

Who's a Fit / Who Isn't

This is not a beginner peptide. Anyone considering Humanin in a research context should already understand sterile reconstitution, sub-Q injection technique, and how to evaluate sourcing. It's most relevant to longevity-focused individuals dealing with cognitive aging concerns, family history of neurodegeneration, or building out an advanced mitochondrial protocol — not someone looking for their first peptide cycle.

Stack Considerations

Humanin doesn't run in isolation in any thoughtful protocol. The mechanistic fit with several other compounds is genuinely good.

Humanin + MOTS-c — The Full Mitochondrial MDP Stack

This is the obvious one. Two peptides, same genome, complementary domains. Humanin covers the neuroprotective and anti-apoptotic side; MOTS-c covers the metabolic and AMPK-driven side. Running both gives you full mitochondrial-derived peptide support — the brain and the heart from Humanin, the muscle and metabolism from MOTS-c. For a longevity-focused protocol in someone over 40, this pairing is the most mechanistically defensible mitochondrial stack on the menu.

Humanin + BPC-157 — Layered Neuroprotection

BPC-157 has its own neuroprotective signature — it modulates dopaminergic and serotonergic systems, supports angiogenesis in CNS tissue, and has shown effects in TBI and stroke models. The mechanisms are non-overlapping with Humanin's. For protocols targeting cognitive resilience, post-concussion recovery, or general neuro-healing, the combination provides two distinct neuroprotective modalities operating in parallel.

Humanin + NAD+ Precursors — Mitochondrial Health Synergy

NAD+ levels and mitochondrial function are tightly coupled. Higher NAD+ availability supports sirtuin activity, mitochondrial biogenesis, and the repair machinery that keeps mitochondria functioning. Humanin works downstream of healthy mitochondrial function — it's a peptide produced by healthy mitochondria. Pairing NAD+ precursors with Humanin addresses both the upstream substrate (NAD+ → sirtuin activity → mitochondrial maintenance) and the downstream signaling (Humanin → neuronal survival, anti-apoptosis). See our NAD+ and peptides longevity guide for the deeper integration logic.

Where Humanin Fits in a Broader Longevity Stack

For full structure on cycling, layering, and timing across longevity peptides, the peptide protocols for anti-aging guide covers how to integrate Humanin and MOTS-c with the rest of the longevity peptide toolkit — Epithalon, GHK-Cu, TA-1, and the GH-axis peptides — without over-stacking or running redundant mechanisms in parallel.

The Honest Limits

A few things worth saying directly:

• The majority of Humanin research is preclinical — cell culture, mouse and rat models, and a growing but still limited set of human observational studies. There are no large, randomized human trials on exogenous Humanin for cognitive aging or longevity outcomes.
• Sourcing matters more than usual. Humanin is not a high-volume research peptide, which means quality variance among research suppliers is real. COA documentation and HPLC verification aren't optional.
• Long-term safety in humans is not established. Most of what's known is from animal models with relatively short exposure windows.
• The FPRL1 and CNTFR receptor systems have other ligands and roles, and chronically activating them with exogenous Humanin in humans hasn't been studied at the depth that — say — GH secretagogue effects have been studied.

None of this means the science is weak. It means Humanin is exactly what it is: an extremely promising longevity target with a strong mechanistic foundation, exciting human observational data, and a research base that hasn't yet caught up to what biohackers and longevity practitioners are interested in doing with it.

Bottom Line

Humanin is one of those rare findings that genuinely changed a textbook. Mitochondria are not just energy producers — they are signaling organs, encoding their own peptides that travel out into the body and modulate aging, cognition, and metabolism in ways the field is still mapping. Humanin is the neuroprotective face of that system. MOTS-c is the metabolic face. Together they represent the most concrete molecular evidence so far that "mitochondrial health" is not just a slogan — it's a measurable, modifiable signaling axis with real downstream consequences for how you age.

For longevity-focused biohackers who already understand the basics and are building protocols at the cellular and mitochondrial level, Humanin is one of the most interesting peptides available to learn about right now. Whether or not it ends up in your stack, understanding how it works is part of understanding modern aging biology.

Ready to build the full stack? The Peptide 101 Complete Bundle includes the Beginner's Guide and the Stacking Guide together — covering peptide selection, reconstitution, dosing, and the complete mitochondrial and longevity stacking protocols for Humanin, MOTS-c, NAD+, and the rest. $19.99. Save $3 vs. buying separately.

Continue Reading

• NAD+ and Peptides: Building a Complete Longevity Stack — The upstream substrate that supports MDP production
• Peptide Protocols for Anti-Aging: A Complete Stack Guide — How Humanin fits into a full longevity protocol
• Thymosin Alpha-1 (TA-1): The Immune Peptide You Haven't Heard Of — Another longevity-relevant peptide for the same protocol stack

This content is for educational purposes only and does not constitute medical advice. Humanin is a research peptide not approved by the FDA for human use. Consult a qualified healthcare professional before starting any peptide protocol.